No one should be caged for a plant, and no one should be denied a treatment that works because the law is fifty years behind the science.
“The science has arrived. The law needs to catch up — now.”
Not anecdotes. Not hype. The clinical and public-health record on cannabis and psychedelic-assisted therapy is strong enough that the question is no longer whether these tools work — it is whether we are brave enough to let them work legally.
Strong evidence · accepted medicine
Cannabinoids reduce chronic pain and neuropathic pain in randomized trials. State medical programs cut opioid prescribing. FDA-approved formulations exist for chemotherapy nausea and rare seizure disorders.
Sources: NASEM 2017, JAMA Internal Medicine opioid studies, FDA Epidiolex / Marinol / Syndros labels
Breakthrough Therapy · Phase 3 complete
MDMA-assisted therapy reduced PTSD symptoms in sponsor trials; FDA granted Breakthrough Therapy status. Trials combine a limited number of dosing sessions with structured preparation and integration therapy.
Sources: FDA Breakthrough Therapy designation, MAPS / Lykos Phase 3 trials
Breakthrough Therapy · FDA-authorized trials
Psilocybin-assisted therapy showed durable effects in patients who failed multiple antidepressants. Regulators in Australia, the US, and several European jurisdictions have authorized clinical access frameworks.
Sources: Johns Hopkins / NYU trials, FDA Breakthrough Therapy, TGA Australia 2023 rescheduling
FDA-approved · clinical use expanding
Esketamine is FDA-approved for treatment-resistant depression. Off-label ketamine clinics operate under medical supervision and have become a legal access point in many countries.
Sources: FDA Spravato approval, ASKP guidelines
Promising · restricted legal access
Observational studies and small trials suggest ibogaine can interrupt opioid withdrawal and reduce craving. Legal access is limited to a few countries, leaving patients to choose between suffering and legal risk.
Sources: Mash et al. observational studies, ICEERS / Global Ibogaine Therapy Alliance safety reports
Public health consensus
Criminal records for possession destroy employment, housing, and family stability. The war on drugs disproportionately targets poor communities and people of color while failing to reduce use or overdose.
Sources: Johns Hopkins-Lancet Commission on Drug Policy and Health, ACLU / Human Rights Watch reports
Legalization without guardrails becomes exploitation. Prohibition without mercy becomes cruelty. This is the middle path: legal, regulated, honest, and centered on the people who were hurt most.
Remove criminal penalties for personal use of all drugs. Redirect enforcement dollars to health services, housing, and employment support.
Create clear, national medical frameworks for cannabis, MDMA-assisted, psilocybin-assisted, ketamine, and ibogaine therapies — with prescribing, screening, and integration standards.
Age limits, potency labeling, tested products, licensed retailers, and public-health messaging. No advertising to children. No unregulated synthetics sold as harmless.
Erase past convictions for possession and low-level distribution. Reinvest cannabis tax revenue and saved enforcement costs into the communities most harmed by prohibition.
Psilocybin, ibogaine, ayahuasca, and cannabis have roots in traditional practice. Patent, profit, and policy must not erase the people who kept these medicines alive.
No vertical monopolies. No marketing to vulnerable people. Price caps for medical access. Public data on safety, outcomes, and equity.
We are not saying “anything goes.” These are powerful tools. They belong in screened, structured, accountable settings — not back rooms, not party culture, and not in isolation.
Global by default
This page is a living statement. We will update it as laws change, evidence grows, and more countries join the shift. If you are working on policy reform anywhere in the world, reach out. We want to help.